Bioventus Earnings Call Signals Profitable Growth Ahead

Bioventus, Inc. ((BVS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Bioventus struck an upbeat tone on its latest earnings call, pointing to accelerating organic growth, widening margins and record cash generation as proof that its turnaround is taking hold. Management acknowledged short-term noise from currency, distributor timing and divestiture effects, but emphasized that these headwinds are temporary against a backdrop of strengthening fundamentals.

Revenue Growth Masks Stronger Organic Momentum

Bioventus reported Q4 revenue of $158 million, up 3% year-over-year, but the headline number understates performance once divestitures are stripped out. Organic growth reached 10% in the quarter, with management underscoring a clear acceleration in the back half of 2025 led by Pain Treatments and Restorative Therapies.

EBITDA Surges as Margins Move Sharply Higher

Adjusted EBITDA jumped to $37 million in Q4, a 30% increase from the prior year as profitability gains outpaced revenue growth. The adjusted EBITDA margin climbed to 23%, about 490 basis points higher year-over-year, and full-year margin expansion of roughly 150 basis points surpassed the company’s 100-basis-point improvement target.

Record Operating Cash Fuels Free Cash Flow Story

The company delivered a record $38 million in cash from operations during the quarter, underscoring the improved earnings quality and working capital discipline. For the full year, operating cash flow nearly doubled to about $75 million, and management now expects 2026 cash from operations to rise another 10% to 17% to a range of $82 million to $87 million.

High Gross Margins Drive Better Earnings and EPS

Bioventus’ adjusted gross margin reached 76% in Q4, an improvement of 180 basis points versus the prior year that helped push bottom-line results higher. Adjusted operating income rose to $33 million and adjusted net income to $20 million, translating into Q4 adjusted EPS of $0.24 and setting the stage for 2026 EPS guidance of $0.73 to $0.77 with earnings expected to grow faster than sales.

Deleveraging and Refinancing Strengthen the Balance Sheet

The company ended the quarter with $51 million of cash and $294 million of debt outstanding, having reduced debt by $29 million after repaying revolver borrowings. Net leverage fell below 2.5 times, and management is targeting a level well under 2.0 times by the end of 2026, helped by a term loan refinancing that is expected to lower interest expense and further support equity value.

New Pain Platforms Gain Traction With Targeted Spend

Pilot launches for peripheral nerve stimulation and platelet-rich plasma treatments have drawn encouraging feedback from physicians and patients, validating Bioventus’ push into these higher-growth pain segments. Management reaffirmed that these platforms should provide at least 200 basis points of growth in 2026 and will be supported by about $13 million of incremental investment across PNS, PRP, ultrasonics and international markets.

Segments Outperform Markets, International Leads the Charge

Across each of its three businesses, Bioventus delivered organic revenue growth that outpaced their respective markets over 2025, reinforcing its competitive positioning. Restorative Therapies posted its strongest organic performance in seven years while the International business grew revenue 11% organically, highlighting the company’s ability to execute beyond the U.S.

Strategy Targets Sustainable Growth and Margin Discipline

For 2026, Bioventus outlined a framework built around net sales of $600 million to $610 million and an adjusted EBITDA margin of about 20% even as it steps up growth investment. Management detailed a multi-year approach that aims to accelerate revenue, resume margin expansion from 2027 and continue deleveraging, balancing reinvestment with disciplined cost management.

Headline Growth Tempered by Divestiture and Mix Effects

Despite robust organic performance, Q4 revenue growth of 3% highlighted the gap between reported and underlying trends, driven largely by portfolio actions and mix factors. Executives cautioned that this volatility can obscure the trajectory of the core business but argued that investors should focus on sustained double-digit organic growth rather than headline comparisons.

Restorative Therapies Hit by Divestiture but Healthy Underneath

Restorative Therapies’ Q4 revenue declined 26% year-over-year as the Advanced Rehabilitation divestiture materially reduced reported sales. Excluding this business, the segment actually delivered 10% organic growth, demonstrating continued demand strength in the remaining portfolio even as the company prunes non-core assets.

FX Losses Weigh on Results but Seen as Transitory

Foreign exchange movements created an unplanned loss of nearly $1 million in Q4, with over $3 million of FX impacts recorded for the full year, slightly clouding the earnings picture. Management framed these currency headwinds as external and temporary, noting that the 2026 outlook assumes no additional U.S. dollar volatility beyond current levels.

Distributor Timing to Reverse, Softening Near-Term Metrics

Some of the Q4 strength came from distributor ordering patterns and an extra selling day, which together added about $2 million to revenue and pulled demand forward. Bioventus expects these factors, along with HA inventory rebalancing and one fewer selling day, to make the first quarter of 2026 the weakest of the year, with growth and EBITDA building toward a stronger fourth quarter.

Ultrasonics Faces Tough Comparisons and Short-Term Volatility

Growth in the ultrasonics business was pressured in Q4 by comparison to an all-time-high level of capital sales in the prior year, muting surgical revenue expansion. Even so, generator revenue still ranked as the third-highest quarter ever, and management framed current volatility as a function of capital cycle timing rather than a deterioration in underlying demand.

Guidance Points to Steady Growth and Deleveraging Ahead

Looking forward, Bioventus guided to 2026 net sales of $600 million to $610 million, adjusted EPS of $0.73 to $0.77 and operating cash flow of $82 million to $87 million, while targeting an adjusted EBITDA margin around 20%. The company expects PNS and PRP to add at least 200 basis points to 2026 growth, plans roughly $13 million of incremental investment and aims to drive net leverage well below 2.0 times by year-end, with the year weighted toward a stronger Q4.

Bioventus’ call painted the picture of a company moving past portfolio cleanup and into a more predictable growth phase, supported by margin gains, cash generation and disciplined debt reduction. While near-term results may be choppy due to FX and timing issues, management’s confidence in its pain-treatment platforms and international expansion suggests that the underlying trajectory remains firmly upward for investors tracking the story.